Generation and Characterization of Recombinant Influenza A(H1N1) Viruses Resistant to Neuraminidase Inhibitors

WooYoung Choi a, Jin-Young Shin b, Hwan-Eui Jeong c, Mi-Jin Jeong b, Su-Jin Kim b, Joo-Yeon Lee b, Chun Kang b, *

aDivision of Arboviruses, Korea National Institute of Health, Osong, Korea. 
bDivision of Influenza Virus, Korea National Institute of Health, Osong, Korea. 
cSK Chemicals, Seongnam, Korea.

Received: September 27, 2013 
Revised: October 16, 2013 
Accepted: October 17, 2013

KEYWORDS: influenza virus, neuraminidase inhibitors, recombinant drug-resistant virus, reverse genetics

Abstract

Objectives: To examine the effect of neuraminidase (NA) mutations on the NA inhibitor (NAI) resistance phenotype, the recombinant influenza A/Chungbuk/4448/2008(H1N1) virus isolated in South Korea during the 2008–2009 season was generated by reverse genetics.

Methods: Site-directed mutagenesis was introduced on the NA gene of A/Chungbuk/4448/2008(H1N1) virus, and a total of 23 single, double, and triple mutants were generated. Resistance phenotype of these recombinant viruses was determined by NA-inhibition (NAI) assays based on a fluorometric method using two NAIs (oseltamivir and zanamivir).

Results: NA-inhibition assays showed that all the single and double mutants containing the Y275 except the single Y275-E119V mutant conferred important levels of resistance to oseltamivir, whereas all the single, double, and triple mutants containing the E119V mutation were associated with the resistance to zanamivir.

Conclusion: Considering the effect of mutations in NA gene on the resistance to NAIs, it is important to monitor the possible emergence and dissemination of multidrug-resistant variants in the human population due to amino acid changes at NA gene as well as to develop novel NAIs.

1. Introduction

Influenza infects approximately 20% of the world’s population, and more than half a million individuals die every year of influenza-associated complications [1]. In 2009, the pandemic influenza A(H1N1) virus spread quickly among humans worldwide to cause the first influenza pandemic of the 21st century [2]. Vaccination and antiviral treatment are essential for the prevention and control of influenza infection. With the use of antiviral drugs for the clinical management of influenza, neuraminidase (NA) inhibitors (NAIs) have

*Corresponding author. 
E-mail: ckang@nih.go.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyright © 2013 Korea Centers for Disease Control and Prevention. Published by Elsevier Korea LLC. All rights reserved.
been proved to be very effective against influenza A and B viruses [3]. However, NAI-resistant strains have been reported frequently [4,5], in case of the emergence during the treatment of drug or dissemination of drug-resistant variants.

Several subtype-specific mutations in framework or catalytic residues of NA that confer resistance to NAIs have been reported [1,6–8]. The dominant change conferring oseltamivir resistance in the current seasonal influenza viruses is a mutation in the NA gene, H275Y (N1 numbering). The frequency of isolates with the H275Y mutation has increased with each flu season, including in countries where oseltamivir is not prescribed regularly. Particularly, most isolated seasonal influenza A(H1N1) viruses during the 2008–2009 season were found to encode the H275Y substitution in the NA gene, conferring resistance to oseltamivir [9]. Other NA mutations (N2 numbering: E119G, H274Y, R292K, and N295S) that have been reported to confer resistance to NAIs were each introduced into recombinant A/Vietnam/1203/04(H5N1) influenza virus [10].

Here we selected A/Chungbuk/4448/2008(H1N1) virus isolated in South Korea during the 2008–2009 season, which was one of the viruses isolated from throughout the country by the Korean Influenza Surveillance Scheme [11]. To investigate the effect of different NA mutations on the NAI resistance phenotype of A/Chungbuk/4448/2008(H1N1) virus, we generated recombinant A/Chungbuk/4448/2008(H1N1) virus using a reverse genetics system, introduced the different NA mutations into the background of the recombinant A/Chungbuk/4448/2008(H1N1) virus, and compared their NAI resistance phenotypes.

2. Materials and methods

2.1. Cells and viruses

Madin Darby canine kidney (MDCK) cells and human embryonic kidney cells transformed with large T antigen (293T cells) were obtained from American Type Culture Collection (Manassas, VA, USA). A/Chungbuk/4448/2008(H1N1) virus isolated in South Korea during the 2008–2009 season was used for the generation of recombinant viruses.

2.2. Antiviral compounds

Tartrate salt of oseltamivir carboxylate (active form of Tamiflu) was provided generously by F. Hoffmann-La Roche, Inc. (Basel, Switzerland); it was dissolved in distilled water such that the final oseltamivir carboxylate concentration was 10 mM. Zanamivir (Relenza), which was provided by GlaxoSmithKline (Stevenage, UK), was dissolved in distilled water to a final zanamivir concentration of 10 mM. Aliquots were stored at −20 °C until use.

2.3. Generation of recombinant viruses and site-directed mutagenesis

Recombinant viruses were generated using the eight-plasmid reverse genetics system with pHW2000 (the vector was provided kindly by Robert Webster, St. Jude Children’s Research Hospital, Memphis, TN, USA) [12]. The eight genes from the cultured A/Chungbuk/4448/2008(H1N1) virus were amplified by reverse transcription polymerase chain reaction (RT-PCR) and incorporated into the pHW2000 plasmid. All eight plasmids were transfected into a coculture of 293T and MDCK cells for 3 days, and then further prepared in 10-day-old embryonated chicken eggs. The collected supernatant from the transfected cells was injected into the allantoic cavities of the eggs and incubated at 37 °C for 3 days to amplify the rescued viruses. The viruses generated in eggs were stored at −80 °C until use.

To investigate mutations at NA key residues (N1 numbering: I117V, I117M, E119V, I223V, Y275H, R293K, N295S, and S334N), site-directed mutagenesis was conducted on the NA gene cloned plasmid using the QuickChange Site-Directed Mutagenesis Kit (Stratagene, Santa Clara, CA, USA). All recombinant plasmids were sequenced to ensure the absence of undesired mutations. The eight plasmids were then cotransfected to 293T mixed with MDCK cells. Supernatants were collected at 3 days post-transfection and used to inoculate specific pathogen-free (SPF) eggs. Introduced mutations of the recombinant wild type virus as well as the NA mutants were confirmed by sequencing.

2.4. NA activity assay and NA inhibition assay

The NA activity of each virus sample was determined by a modified fluorometric assay that measured 4-methylumbelliferyl released from the fluorogenic substrate 2′-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid (MUNANA; Sigma-Aldrich, St. Louis, MO, USA) by the enzymatic activity of the influenza virus NA [13,14].

The drug resistance phenotype was determined by NA inhibition assays using the MUNANA (Sigma) substrate, with minor modifications [13–15]. The viruses were tested for susceptibility to oseltamivir and zanamivir. To determine the drug concentration required to inhibit 50% of the NA activity [50% inhibitory concentration (IC50)], 50 μL of virus, diluted according to the NA activity assay, was mixed with various concentrations of inhibitor in microtiter plates (FluoroNunc plates; Nalge Nunc International, Penfield, NY, USA). The final reaction mixture concentration of the NAIs ranged from 0.01 nM to 10,000 nM. The virus–inhibitor mixture was incubated at room temperature for 45 minutes prior to the addition of 50 μL of the MUNANA substrate (0.3 mM) and then incubated at 37 °C for 60 minutes. The reaction was terminated by the addition of 100 μL of the stop solution. The IC50 for each drug was calculated from the dose–response curve using GraphPad Prism software, version 5 (San Diego, CA, USA). The sensitive viruses
belonged to an IC$_{50}$ range of 0.001–15 nM for zanamivir and 0.001–25 nM for oseltamivir carboxylate. The resistant viruses belonged to both inhibitors in the IC$_{50}$ range from 43 nM to as high as 8020 nM [15].

3. Results

3.1. Generation of recombinant wild type and NA mutant influenza viruses by reverse genetics system

The recombinant wild-type [A/Chungbuk/4448/2008(H1N1)] virus was generated by reverse genetics. That is, the eight genes of A/Chungbuk/4448/2008(H1N1) virus (PB2, PB1, PA, HA, NP, NA, M, and NS) were amplified by RT-PCR (data not shown). The PCR products were then inserted into pHW2000 vector. After the cell transfection with these eight plasmids, supernatants were collected at 3 days post-transfection and used to inoculate SPF eggs. The generation of recombinant wild-type virus was confirmed by sequencing.

We used mutagenesis and plasmid-based reverse genetics to generate recombinant A/Chungbuk/4448/2008(H1N1) viruses containing either the wild-type NA (Y275) or a single amino acid change at NA residue 117 (I→V), 117 (I→M), 119 (E→V), 223 (I→V), 275 (Y→H), 293 (R→K), 295 (N→S), or 334 (S→N). For example, the recombinant Chungbuk-Y275-I117V virus contained an I→V amino acid change at residue 117 of NA in the wild-type virus [A/Chungbuk/4448/2008(H1N1)] and the recombinant Chungbuk-Y275H-I117V virus contained Y275H and I117V amino acid changes at residues 117 and 275 of NA in the wild-type virus, respectively (numbering is based on the N1 NA protein throughout). Totally, eight single mutants (Y275-I117V, Y275-I117M, Y275-E119V, Y275-I223V, Y275H, Y275-R293K, Y275-N295S, and Y275-S334N), 10 double mutants (Y275H-I117V, Y275H-I117M, Y275H-E119V, Y275H-I223V, Y275H-R293K, Y275H-N295S, Y275H-S334N, Y275-N295S-I117V, Y275-N295S-I117M, and Y275-N295S-I223V), and five triple mutants (Y275H-E119V-I117V, Y275H-E119V-I117M, Y275H-N295S-I117V, Y275H-N295S-I117M, and Y275H-N295S-I223V) were generated (Table 1). Introduced mutations of the recombinant NA mutants were confirmed by sequencing.

3.2. Susceptibility of recombinant wild-type and NA mutant influenza viruses to NAIs in vitro

An enzymatic NA inhibition assay was used to characterize the susceptibilities of recombinant A/Chungbuk/4448/2008(H1N1) virus and each of the 23 mutants to oseltamivir and zanamivir (Table 2). NA-inhibition assays showed that E119V mutation of the wild-type virus containing tyrosine (Y) at NA residue 275 (Chungbuk-Y275-E119V) and E119V mutation of

Table 1. Generation of the recombinant influenza A(H1N1) viruses.

| NA mutation | Single mutant | Double mutant | Triple mutant |
|-------------|---------------|---------------|---------------|
| I117V       | Chungbuk-Y275H-I117V | Chungbuk-Y275H-I117MV | Chungbuk-Y275H-I117MV |
| I117M       | Chungbuk-Y275H-I117M | Chungbuk-Y275H-I117MV | Chungbuk-Y275H-I117MV |
| E119V       | Chungbuk-Y275H-E119V | Chungbuk-Y275H-E119VM | Chungbuk-Y275H-E119VM |
| I223V       | Chungbuk-Y275H-I223V | Chungbuk-Y275H-I223VM | Chungbuk-Y275H-I223VM |
| R293K       | Chungbuk-Y275H-R293K | Chungbuk-Y275H-R293KM | Chungbuk-Y275H-R293KM |
| N295S       | Chungbuk-Y275H-N295S | Chungbuk-Y275H-N295SM | Chungbuk-Y275H-N295SM |
| S334N       | Chungbuk-Y275H-S334N | Chungbuk-Y275H-S334NM | Chungbuk-Y275H-S334NM |

*NA numbering: Wild-type virus; NA mutant virus at N1 residue 275 (Y→H). NA = neuraminidase.
the mutant virus containing histidine (H) at NA residue 275 (Chungbuk-Y275H) conferred important levels of resistance to zanamivir, with 202.5-fold and 135.7-fold increases in IC50 values compared with that of the wild-type virus (Chungbuk-Y275) and Chungbuk-Y275H mutant virus, respectively, whereas these mutants were susceptible to oseltamivir. Compared with the single Chungbuk-Y274H mutant, triple Chungbuk-Y275H-E119V-I117V and Y275H-E119V-I117M mutants had increased IC50 values for zanamivir (390.7-fold and 181.0-fold), whereas these mutants were susceptible to oseltamivir. All the single, double, and triple mutants containing the E119V mutation were associated with the resistance to zanamivir.

All the single and double mutants containing tyrosine (Y) at NA residue 275 of the wild-type virus except the single mutant (Chungbuk-Y275-E119V) conferred important levels of resistance to oseltamivir, whereas the wild-type virus and these mutants were associated with the susceptibility to zanamivir. The N295S mutation in the wild-type virus (Chungbuk-Y275-N295S) was associated with a reduction in oseltamivir resistance (0.2-fold decrease in IC50 compared with that of the wild-type virus), whereas N295S mutation of the mutant virus containing histidine (H) at NA residue 275 (Chungbuk-Y275H-N295S) was associated with an increase in oseltamivir resistance (40.3-fold increase in IC50 compared with that of Chungbuk-Y275H mutant virus). Compared with the double Chungbuk-Y274H-N295S mutant, triple Chungbuk-Y275H-N295S-I117V, Y275H-N295S-I117M, and Y275H-N295S-I223V mutants also had slightly increased IC50 values for oseltamivir (1.5-fold, 1.3-fold, and 2.4-fold), whereas these mutants were susceptible to zanamivir. The single I117V, I117M, I223V, R293K, N295S, or S334N mutation did not seem to contribute significantly to a phenotype resistant to oseltamivir as well as to zanamivir.

4. Discussion

Although many subtype-specific NA mutations conferring resistance to NAIs in influenza A(H1N1),
A(H3N2), and A(H5N1) viruses have been reported previously [1,4–8,10,16–18], differences in viral backgrounds can account for a differential effect of these mutations on antiviral resistance or viral fitness.

Hence, we generated a recombinant wild-type A(H1N1) virus and its 23 mutants using a reverse genetics system to examine the effect of NA mutations on the NAI resistance phenotype. We used A/Chungbuk/4448/2008(H1N1) virus, which was isolated in South Korea during the 2008–2009 season as a wild-type virus.

NA-inhibition assays showed that all the single and double mutants containing the Y275, except the single Y275-E119V mutant, conferred important levels of resistance to oseltamivir, whereas all the single, double, and triple mutants containing the E119V mutation were associated with the resistance to zanamivir (Table 2).

In combination with Y275, the I117V or I223V mutation has a synergistic effect on oseltamivir resistance, increasing IC50 values of oseltamivir by 1.3-fold and 1.1-fold, respectively, compared to the values caused by the Y275 mutation alone. Addition of the N295S mutation to the Y275H mutation has a synergistic effect on oseltamivir resistance, increasing the IC50 value of oseltamivir to 40.3-fold of that of the Y275H mutation alone, whereas the addition of the N295S mutation to the Y275 has an antagonistic effect on oseltamivir resistance, decreasing the IC50 value of oseltamivir to 0.2-fold of that of the Y275 alone.

The I117M mutation was detected in a pandemic (H1N1) 2009 virus from South Korea that was isolated from a patient during oseltamivir treatment [19]. The I117V mutation was detected in influenza A(H5N1) virus [20]. A previous study has reported that I117V has a synergistic effect of increasing resistance with H275Y, whereas the I117M mutation does not alter oseltamivir sensitivity in the recombinant viruses with NA from the pandemic (H1N1) 2009 virus and the remaining genes from A/PR/8/34 [21]. In this study, we had similar results in case of the recombinant A/Chungbuk/4448/2008(H1N1) virus.

In summary, I117V or I223V mutation has increased the resistance to oseltamivir in combination with Y275 virus, whereas N295S mutation has decreased resistance to oseltamivir in combination with Y275 virus. Different amino acid substitutions at key NA residues can cause considerably different effects on NA1 susceptibility.

Here, we showed the NA activities of recombinant wild-type and NA mutant influenza viruses to NAIs in vitro. Further in vivo and clinical studies are required to investigate the effect of these drug-resistant mutants.

Considering the effect of mutations in NA gene on the resistance to NAIs, it is important to monitor the possible emergence and dissemination of multidrug-resistant variants in the human population due to amino acid changes at NA gene as well as the to develop novel NAIs.

Acknowledgments

This study was supported by the intramural research fund (code #2011-N43004-00) of the Korea National Institute of Health.

References

1. Pizzorno A, Bouhy X, Abed Y, Boivin G. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. J Infect Dis 2011 Jan;203(1):25–31.
2. Centers for Disease Control and Prevention (CDC). Update: novel influenza A(H1N1) virus infections-worldwide, 2009 May 6. MMWR Morb Mortal Wkly Rep 2009 May 8;58:453–8.
3. Englund JA. Antiviral therapy of influenza. Semin Pediatr Infect Dis 2002 Apr;13(2):120–8.
4. Dharian NJ, Gubareva LV, Meyer JJ, et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009 Mar;301(10):1034–41.
5. Sheu TG, Deyde VM, Okuno-Adhiambio M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008 Jul;52(9):2824–92.
6. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004 Aug—Sep;364(9436):759–65.
7. Monto AS, McKimm-Breschkin JL, Macken C, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006 Jul;50(7):2395–402.
8. Moscona A. Global transmission of oseltamivir-resistant influenza. N Engl J Med 2009 Mar;360:953–6.
9. WHO. Influenza A virus resistance to oseltamivir and other antiviral medicines. Available from: http://www.who.int/csr/disease/influenza/2008-9hemisummaryreport/en/index.html. [accessed 25.02.10].
10. de Jong MD, Tan TT, Truong HK, et al. Oseltamivir resistance during treatment of influenza A(H5N1) infection. N Engl J Med 2005 Dec;353:2667–72.
11. Choi WY, Yang IS, Kim SJ, et al. The emergence of oseltamivir-resistant seasonal influenza A(H1N1) virus in Korea during the 2008–2009 season. Public Health Res Perspect 2011 Sep;2(3):178–85.
12. Hoffmann E, Krauss S, Perez D, et al. Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine 2002 Aug; 20(25–26):3165–70.
13. Hurt AC, Barr IG, Hartel G, Hampson AW. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. Antiviral Res 2004 Apr;62(1):37–45.
14. NISN Website. Available from: http://www.nisn.org/v_anlysis_guidance_ic50.php. [accessed 28.05.10].
15. WHO Collaborating Centre for Reference & Research on Influenza. Standard operating procedure WHO—025; fluorometric neuraminidase inhibition assay. Australia: WHO Collaborating Centre for Reference & Research on Influenza; 2007.
16. Aoki FY, Boivin G, Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther 2007;12(4):603–16.
17. Hurt AC, Holien JK, Barr IG. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob Agents Chemother 2009 Oct;53(10):4433–40.
18. McKimm-Breschkin JL. Resistance of influenza viruses to neuraminidase inhibitors. Antiviral Res 2000 May;47:1–17.
19. Yi H, Lee J-Y, Hong E-H, et al. Oseltamivir-resistant pandemic (H1N1) 2009 virus, South Korea. Emerg Infect Dis 2010 Dec; 16(12):1938–42.

20. Hurt AC, Selleck P, Komadina N, et al. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res 2007 Mar;73(3):228–31.

21. Hurt AC, Leang SK, Speers DJ, et al. Mutations I117V and I117M and oseltamivir sensitivity of pandemic (H1N1) 2009 viruses. Emerg Infect Dis 2012 Jan;18(1):109–12.